SANUWAVE Health, Inc. announced that it has received $4.6 million in funding
January 20, 2024
Share
SANUWAVE Health, Inc. announced that it has entered into a Securities Purchase Agreement with the purchasers to issue convertible promissory notes for the gross proceeds of $4,600,000 on January 21, 2024. The principal amount of the notes is $4,600,000 and an additional 113,900,000 shares of common stock of the Company with an exercise price of $0.067 per share (the ?First Warrants?) and Common Stock Purchase Warrants to purchase an additional 113,900,000 hares of common stock of the Company with an exercise price of $0.04 per share. The Warrants have a five-year term and received total proceeds of $4,600,000. The notes are converted at a conversion price of $0.04 per share. The securities in the Private Placement were offered and sold in a transaction exempt from registration under the Securities Act in reliance on Section 4(a)(2) thereof. Each Purchaser represented that it was an accredited investor. Interest rate of notes is 15% per annum, compounded annually.
The company has raised $4,557,650 pursuant to Regulation D from 19 investors.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.
SANUWAVE HEALTH, INC. 
